

Update Notes

Update Summary

Inactivate Test With Replacement

7/8/2020

[HGRIT - "HIV-1 Genotype \(RTI, PI, Integrase Inhibitors\)" replaced by HIVTO - "HIV-1 Genotype \(RTI, PI, Integrase Inhibitors\)"](#)

Inactivate Test With Replacement			
Effective Date	7/8/2020		
Inactivated Test			
Name	HIV-1 Genotype (RTI, PI, Integrase Inhibitors)		
Code	HGRIT		
Legacy Code¹	HGRIT		
Interface Order Code	3431201		
Notes			
Replacement Test			
Name	HIV-1 Genotype (RTI, PI, Integrase Inhibitors)		
Code	HIVTO		
CPT Code(s)	87900, 87901, 87906		
Notes			
Specimen Requirements			
Specimen Required	Draw blood in a lavender EDTA. Centrifuge and separate plasma from cells within 24 hours. Send 5.0 mL plasma (1.6 mL minimum) frozen in a screw-capped plastic vial.		
Alternate Specimen			
Rejection Criteria	Gross hemolysis, lipemia, serum, whole blood, heparinized plasma		
Stability	Room temperature: 24 hours; Refrigerated: 5 days; Frozen: 35 days		
Performing Information			
Methodology	Reverse Transcriptase Polymerase Chain Reaction (TR-PCR), Sequencing		
Reference Range	By report		
Performed Days	Monday - Saturday		
Turnaround Time	6 - 11 days		
Performing Laboratory	Quest SJC		
Interface Information			
Legacy Code¹	HIVTO		
Interface Order Code	3400342		
Result Code	Name	LOINC Code	AOE/Prompt ²
3400343	HIV-1 Genotype	48558-1	No
3400344	Value of Last Viral Load	19146-0	Yes
3400345	Date Viral Load Collected	33882-2	Yes
3400346	Raltegravir Resistance	72525-9	No
3400347	Elvitegravir Resistance	72536-7	No
3400348	Dolutegravir Resistance	72857-6	No
3400349	Bictegravir Resistance	90080-3	No



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000003039 M 12/05/1988 31 Y

Referral Testing

Collected: 07/02/2020 12:44 Received: 07/08/2020 12:44

Test Name Result Flag Ref-Ranges Units Site

HIV-1 Genotype (RTI, PI, Integrase Inhibitors)

HIV-1 Genotype NOT DETECTED QCRL

The method used in this test is RT-PCR and sequencing Of the HIV-1 polymerase gene.

The phrases 'resistance predicted' and 'probable Or emerging resistance' refer to the application of The interpretive rules. The FDA has not reviewed all of the interpretive rules used by the laboratory to predict drug resistance. FDA may not currently recognize some of the HIV gene mutations reported as predictive of drug resistance, but the laboratory considers these mutations to be associated with resistance to anti-viral drugs based on current clinical or scientific studies. The test has been validated pursuant to CLIA regulations and is not considered investigational or for research use only. Treatment decisions should be made in consideration of All relevant clinical and laboratory findings and the prescribing information for the drugs.

This test was developed and its analytical Performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Test Performed at: Quest Diagnostics Infectious Disease, Inc. 33608 Ortega Highway San Juan Capistrano, CA 92675-2042 H J Batterman MD

Value of Last Viral Load 456 QCRL
Date Viral Load Collected 6/30/2020 QCRL
Raltegravir Resistance NOT PREDICTED QCRL
Elvitegravir Resistance NOT PREDICTED QCRL
Dolutegravir Resistance NOT PREDICTED QCRL
Bictegravir Resistance NOT PREDICTED QCRL

The method used in this test is RT-PCR and sequencing of the HIV-1 integrase gene. The phrases "resistance predicted" and "probable or emerging resistance" refer to the application of the interpretive rules. The FDA has not reviewed all of the interpretive rules used by the

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000003039 M 12/05/1988 31 Y

Referral Testing

Collected: 07/02/2020 12:44

Received: 07/08/2020 12:44

Test Name Result Flag Ref-Ranges Units Site

laboratory to predict drug resistance. FDA may not currently recognize some of the HIV gene mutations reported as predictive of drug resistance, but the laboratory considers these mutations to be associated with resistance to anti-viral drugs based on current clinical or scientific studies.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

For more information on this test, go to:
http://education.questdiagnostics.com/faq/FAQ135
(This link is being provided for informational/educational purposes only.)

Test Performed at:
Quest Diagnostics Infectious Disease, Inc.
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042 H J Batterman MD

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

B50800001 Ordered By: CLIENT CLIENT
WX0000003039 WX0000000001595
Printed D&T: 07/08/20 12:49

William G. Finn, M.D. - Medical Director
Form: MM RL1
PAGE 2 OF 2